1 |
Convalescent Plasma |
Interventional (Phase 1) |
Treatment |
20 |
Hospital San Jose Tec de Monterrey (NCT04333355) |
2 |
Anti-SARS-CoV-2 convalescent plasma |
Interventional (Early Phase 1) |
Treatment |
20 |
Orthosera Kft. (NCT04345679) |
3 |
Convalescent Plasma Transfusion |
Interventional (Phase 2) |
Treatment |
20 |
Institute of Liver and Biliary Sciences, India (NCT04346446) |
4 |
Convalescent Plasma |
Interventional (Phase 2) |
Treatment |
15 |
Saint Francis Care (NCT04343261
|
5 |
COVID-19 convalescent plasma |
Expanded Access |
Treatment |
Expanded Access |
Mayo Clinic (NCT04338360) |
6 |
Transfusion of COVID-19 convalescent plasma |
Interventional (Phase 2) |
Treatment |
120 |
Assistance Publique - Hôpitaux de Paris (NCT04345991) |
7 |
convalescent plasma from recovered COVID 19 donor |
Interventional (Phase 2) |
Treatment |
40 |
King Fahad Specialist Hospital Dammam (NCT04347681) |
8 |
Convalescent Plasma |
Interventional (Phase 1/2) |
Treatment |
500 |
Stony Brook University (NCT04344535) |
|
Standard Donor Plasma |
|
|
|
|
9 |
Convalescent Plasma |
Interventional (Phase 2) |
Treatment |
55 |
Hackensack Meridian Health (NCT04343755) |
10 |
Convalescent Plasma |
Interventional (Phase 2) |
Treatment |
426 |
Erasmus Medical Center (NCT04342182) |
11 |
Convalescent Plasma |
Interventional (Phase 2) |
Treatment |
278 |
Cristina Avendaño Solá (NCT04345523) |
12 |
Convalescent Plasma |
Interventional (EarlyPhase1) |
Treatment |
10 |
University of Chicago (NCT04340050) |
13 |
Plasma Hydroxychloroquine |
Interventional (Phase 1/2) |
Treatment |
80 |
Universidad del Rosario (NCT04332835) |
|
Azithromycin |
|
|
|
|
14 |
Convalescent Plasma |
Interventional |
Treatment |
30 |
Mazandaran University of Medical Sciences (NCT04327349) |
15 |
Convalescent Plasma |
Observational |
|
15 |
Shanghai Public Health Clinical Center (NCT04292340) |
16 |
Anti- SARS-CoV-2 Plasma SARS-CoV-2 non-immune Plasma |
Interventional (Phase 2) |
Treatment |
150 |
Johns Hopkins University (NCT04323800) |
17 |
Convalescent anti-SARS-CoV-2 plasma Sarilumab, Baricitinib, Hydroxychloroquine |
Interventional (Phase 3) |
Treatment |
1500 |
Thomas Benfield (NCT04345289) |
18 |
high-titer anti-Sars-CoV-2 plasma, oxygen therapy |
Interventional (Phase 1) |
Treatment |
115 |
Baylor Research Institute (NCT04333251) |
19 |
Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from a convalescent patient |
Interventional |
Treatment |
10 |
A.O. Ospedale Papa Giovanni XXIII (NCT04346589
|